An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer
Background Although combining targeted agents with conventional, first-line cytotoxic therapy has improved survival outcomes in patients with advanced colorectal cancer, further improvements in outcomes and tolerability are needed. Methods This phase I study evaluated the feasibility of combining or...
Main Authors: | Brady, J, Corrie, P, Chau, I, Digumarti, R, Adams, L, Botbyl, J, Laubscher, K, Midgley, R, Mallath, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2013
|
Similar Items
-
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
by: Brady, J, et al.
Published: (2013) -
A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer
by: Brady, J, et al.
Published: (2009) -
CapeOX as neoadjuvant chemotherapy for locally advanced rectal cancer: might less be more?
by: Tianan Guo, et al.
Published: (2024-10-01) -
Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer
by: Zuo Fei, et al.
Published: (2019-04-01) -
Case Report: Primary small bowel adenocarcinoma with peritoneal metastasis responded well to a CapeOX + bevacizumab regimen
by: Guang Fu, et al.
Published: (2023-08-01)